

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
24 November 2022 (24.11.2022)



(10) International Publication Number  
**WO 2022/246225 A1**

(51) International Patent Classification:

A61K 38/39 (2006.01) C07K 16/28 (2006.01)  
C07K 14/78 (2006.01) A61P 37/06 (2006.01)

(21) International Application Number:

PCT/US2022/030290

(22) International Filing Date:

20 May 2022 (20.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/191,514 21 May 2021 (21.05.2021) US  
63/235,520 20 August 2021 (20.08.2021) US

(71) Applicant: **VIELA BIO, INC.** [US/US]; One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878 (US).

(72) Inventors: **ILLEI, Gabor**; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **ALEVIZOS, Ilias**; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **DRAPPA, Jorn**; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **REES, William**; c/o Viela Bio,

Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **BROWN, Fraser** et al.; COOLEY LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CD40L ANTAGONIST AND USES THEREOF IN THE TREATMENT OF LUPUS NEPHRITIS




FIG. 1

(57) Abstract: A human CD40L-specific Tn3 molecule and therapeutic uses thereof for the treatment of lupus nephritis are provided herein. Also provided are therapeutic regimens that comprise a CD40L-specific Tn3 scaffold.

WO 2022/246225 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*